- Policy
- Saxenda must be prescribed thru outpatient Rx
- by Lee, Jeong-Hwan Oct 23, 2020 09:44am
- The MFDS stated that the principle is to issue outpatient Rx by applying the principle of separation of prescribing and dispensing drugs for self-injectable medicines such as obesity drug, Saxenda. Unless a doctor directly injects, according to the purpose of separation of prescribing and dispensing drugs, medical institutions such as hosp
- Policy
- NA audit talks about pre-listing coverage on anticancer
- by Lee, Hye-Kyung Oct 23, 2020 09:44am
- At the National Assembly annual audit, a healthcare provider suggested the ‘pre-listing reimbursement and post-evaluation’ should be implemented and ‘incremental cost-effectiveness ratio (ICER) threshold’ should be adjusted to practically improve access to new drugs. Professor Kang Jin-hyoung at the Catholic University of Korea Seoul
- Policy
- Patients taking more than 10 drugs exceeded 2 million
- by Lee, Jeong-Hwan Oct 22, 2020 06:45am
- The number of multi-drug-drug patients who took more than 10 drugs at once exceeded 2 million last year. Korea ranks the highest among seven OECD countries that submitted statistics on multi-drug consumption, and the situation is serious. On the 20th, In Jae-keun, a member of Democratic Party of Korea, analyzed the national control data submi
- Policy
- 9 non-reimbursement vaccines could save ₩40 billion
- by Lee, Jeong-Hwan Oct 22, 2020 06:43am
- It was argued that expanding the National Immunization Program (NIP) and including non-reimmbursement vaccines in the scope of health insurance coverage would be effective in reducing socioeconomic losses and strengthening health insurance finances. It is pointed out that it is possible to reduce the socio-economic cost of &8361;39.9 billion
- Policy
- Eplerenone was first approved in Korea
- by Lee, Tak-Sun Oct 22, 2020 06:31am
- The drug for hypertension and chronic renal failure, which was not introduced in Korea, was first approved by a small and medium-sized pharmaceutical company in Korea. The MFDS approved a drug for data-based re-evaluation of two doses of Theragen Etex's Eplerenone formulation on the 21st. Eplerenone is generic for Inspra, which was app
- Policy
- Competition for generics for Tenelia M SR is fierce
- by Lee, Tak-Sun Oct 21, 2020 06:35am
- Following Handok's DPP-4 inhibitory diabetes treatment 'Tenelia', the generics for 'Tenelia M SR', a combination drug combined with Metformin, are also actively developing commercialization. According to the MFDS on the 20th, this year, Kyung Dong and Kolmar Korea were approved for a phase I clinical trial to compare the equivalence of th
- Policy
- Sneak peek into NHIS-HIRA audit centering new drug coverage
- by Lee, Jeong-Hwan Oct 21, 2020 06:32am
- The National Assembly annual audit for National Health Insurance Service (NHIS) and Health Insurance Review and Assessment Service (HIRA) scheduled on Oct. 20 is predicted to address the issue of improving patients’ coverage on new drugs like high-cost anticancer treatment. The lawmakers would likely to talk about the necessity of legis
- Policy
- MFDS evaluates documents for prolonged COVID-19 crisis
- by Lee, Tak-Sun Oct 21, 2020 06:32am
- The MFDS decided to skip the pre-GMP survey of imported drugs due to the prolonged COVID-19, and to evaluate the documents without exception. The MFDS postponed the survey after the massive outbreak of COVID-19 in February, and document evaluation was conducted for some items without the survey. However, as COVID-19 situation is prolonged
- Policy
- The intervention in COVID-19 patents should be cautious
- by Lee, Jeong-Hwan Oct 20, 2020 09:16am
- The MOHW said that the government's intervention in a patent related to a vaccine and treatment for COVID-19 developed with public funds from the government should be carefully reviewed. Requesting nation share in patent rights or property rights of private companies just because vaccines and treatments were developed with government fund
- Policy
- Government unconvinced of pre-listing reimbursement
- by Kim, Jung-Ju Oct 20, 2020 09:16am
- The South Korean government has technically expressed its opposing stance at a National Assembly audit session questioning about the necessity of adopting the ‘pre-listing reimbursement and post-evaluation system’ that exempts a deliberation on reimbursement feasibility to enhance a severe-case patient’s treatment access. Considering
